Screener
Travere Therapeutics, Inc. TVTX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax benefit (provision) on continuing operations | 120 | (39) |
| Loss from continuing operations, net of tax | (36,602) | (41,226) |
| Loss from discontinued operations, net of tax | (500) | — |
| Net loss | $(37,102) | $(41,226) |
| Per share data | ||
| Basic and diluted: | ||
| Net loss per common share | $(0.40) | $(0.47) |
| Weighted average common shares outstanding | 91,868,862 | 88,355,973 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s net income?
- Travere Therapeutics, Inc. (TVTX) reported net income of -$37.1M in Q1 2026.
- How has Travere Therapeutics, Inc.'s net income changed year-over-year?
- Travere Therapeutics, Inc.'s net income increased by 10.0% year-over-year, from -$41.23M to -$37.1M.
- What is the long-term trend for Travere Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s net income has grown at a 21.3% compound annual growth rate (CAGR), from -$180.09M to -$321.55M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Travere Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude